O Shaughnessy Asset Management LLC Sells 2,634 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

O Shaughnessy Asset Management LLC cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 30.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,147 shares of the biopharmaceutical company's stock after selling 2,634 shares during the period. O Shaughnessy Asset Management LLC's holdings in Regeneron Pharmaceuticals were worth $4,379,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of REGN. Norges Bank bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $802,036,000. Amundi grew its position in Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after buying an additional 487,489 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after acquiring an additional 393,997 shares during the period. Proficio Capital Partners LLC raised its holdings in Regeneron Pharmaceuticals by 92,865.3% in the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after acquiring an additional 219,162 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $127,489,000. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on REGN. Piper Sandler decreased their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research report on Friday, January 10th. Robert W. Baird reduced their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 5th. Citigroup cut their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Finally, Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target on the stock. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $966.88.

Remove Ads

Regeneron Pharmaceuticals Trading Down 0.1 %

Regeneron Pharmaceuticals stock traded down $0.67 during mid-day trading on Monday, hitting $572.78. 1,678,963 shares of the stock were exchanged, compared to its average volume of 691,944. The stock has a market capitalization of $62.62 billion, a price-to-earnings ratio of 14.96, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a 12 month low of $557.83 and a 12 month high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm's fifty day simple moving average is $674.46 and its two-hundred day simple moving average is $772.53.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $11.86 earnings per share. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.